Precision oncology in RCC has historically focused on clear cell histology, but emerging evidence suggests that pRCC harbours distinct molecular alterations, such as MET, CDKN2A, and NRF2 pathway aberrations, which may inform future treatment approaches [21]. This evidence concerns the gene CDKN2A and renal cell carcinoma.